Compass therapeutics news. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel Targeted Oncology Days taking place virtually Aug 12, 2024 · Analyst Joseph Pantginis from H. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced a clinical trial collaboration and supply agreement with Merck (known as MSD outside the United States and Canada). (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will present at the 2022 Wedbush PacGrow Healthcare Conference that will take place virtually August 9 – 10, 2022. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based We would like to show you a description here but the site won’t allow us. May 13, 2024 · BOSTON, May 13, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference Nov 2, 2022 · BOSTON, Nov. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human Aug 7, 2024 · BOSTON, Aug. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced poster presentations on CTX-009, the Company’s Mar 13, 2024 · Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that its Board of Directors has appointed Thomas Schuetz, M. , June 23rd, 2020 — Compass Therapeutics, a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced the closing of a $60 million private placement financing and the completion of a reverse merger transaction with Olivia Ventures, Inc. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Aug 23, 2024 · CMPX | Complete Compass Therapeutics Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2023. (“Compass”; Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the first patient has been dosed in the Phase 1b study of CTX-471 in Find the latest Compass Therapeutics Inc. (Nasdaq: CMPX), (“Compass”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it has entered into a securities purchase agreement with a select group of institutional investors to issue and Dec 15, 2022 · BOSTON, Dec. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody Apr 25, 2024 · About Compass Therapeutics Compass Therapeutics, Inc. study of CTX-009 in 18 hours ago · Compass Therapeutics, Inc. , Ph. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced the presentation of data from a Phase 2 study of CTX-009 in combination with paclitaxel in patients Aug 3, 2023 · Continuing to enroll patients in a U. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human Nov 9, 2023 · Compass Therapeutics Inc (NASDAQ:CMPX) reported a net loss of $10. About Compass Therapeutics. 's business for stockholders, potential investors, and financial analysts. The firm is developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and Jan 23, 2023 · Investors Dial: 1-877-704-4453 Int’l Investors Dial: 1-201-389-0920 Conference ID: 13735887 Dec 1, 2022 · BOSTON, Dec. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of September 2024. CAMBRIDGE, Mass. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics BOSTON, Nov. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the Stifel 2023 Virtual Targeted Oncology Days, which is Aug 6, 2024 · BOSTON, Aug. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced an upcoming poster presentation of its novel anti-CD137 agonist antibody, CTX-471, in patients with Jun 4, 2024 · CTX-471 is an agonistic antibody directed against the co-stimulatory molecule CD137 (4-1BB). (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics May 4, 2023 · About Compass Therapeutics. The Investor Relations website contains information about Compass Therapeutics, Inc. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. , President of Research and Mar 21, 2024 · BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (CMPX) stock price, news, historical charts, analyst ratings and financial information from WSJ. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary May 28, 2024 · BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics Nov 2, 2021 · BOSTON--(BUSINESS WIRE)--Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the first patient has been dosed in its Phase 1 dose-escalation clinical trial of CTX-8371, a BOSTON, Oct. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human May 4, 2022 · BOSTON, May 04, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that it completed enrollment of the planned 150 patients in COMPANION-002, its randomized Phase 2/3 Apr 10, 2024 · BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. Upon completion of the ongoing Phase 1/2 study, and together with Jan 5, 2024 · Compass Therapeutics, Inc. 03, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human Feb 28, 2024 · BOSTON, Feb. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced it will be presenting at the following investor conferences during the month of November 2022. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. Jan 5, 2024 · About Compass Therapeutics Compass Therapeutics, Inc. 11, 2022 Compass Therapeutics stock up 40% in two days following insider buys Get the latest Compass Therapeutics Inc. Schuetz, MD, PhD has over 20 years of experience in oncology, biopharmaceutical drug development and life science venture investing. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that the U. Colorectal Cancer. 00. Phase 2 study of CTX-009 (DLL4 /VEGF-A bispecific antibody) in patients with advanced colorectal cancer (CRC); initial data from this study is expected in the second half of 2023 Opened 20 clinical sites and continues to enroll patients in a U. BOSTON--(BUSINESS WIRE)-- Compass Therapeutics, Inc. 05, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. Depending on study results, this study may support a biologics Apr 16, 2024 · BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (the "Company") sets high standards for the Company's employees, officers and directors. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer Mar 24, 2024 · Compass Therapeutics Inc is a clinical-stage biopharmaceutical company. Jan 20, 2022 · About Compass Therapeutics. 28, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based We are developing next generation antibodies into transformative cancer therapies that improve patients’ lives. Development Pipeline. (“Compass”; Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the first patient has been dosed in the Phase 2 U. Menu icon A vertical stack of three evenly spaced horizontal lines. 0 million in Q3 2022. C. (the “Company”), a clinical stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced that it intends to offer and sell shares of common stock in an underwritten public offering. 0 million for Q3 2023, a decrease from $12. Oct 8, 2021 · About Compass Therapeutics. (OTCQB: CMPX), a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced that Thomas Schuetz, MD, PhD, Nov 26, 2018 · CAMBRIDGE, Mass. Jan 19, 2023 · BOSTON, Jan. Additional Formats. CAMBRIDGE, Mass, July 12, 2018 – Compass Therapeutics , a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced the closing of the final $49 million of its $132 million Series A financing. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported additional interim results from a Phase 2 study of CTX-009 in combination with paclitaxel in patients BOSTON, Jan. CD137, a member of the TNF receptor superfamily of proteins, provides a potent costimulatory signal to activated T cells and other effector cells within the innate and adaptive arms of the immune system. (CMPX) stock quote, history, news and other vital information to help you with your stock trading and investing. (Nasdaq: CMPX), (“Compass”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics View the latest Compass Therapeutics Inc. We’re leveraging our understanding of the tumor microenvironment to develop product candidates that are designed to optimize critical components required for an effective anti-tumor response to cancer BOSTON, Sept. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human Nov 9, 2023 · About Compass Therapeutics. The company ended Q3 with $164 million in cash and marketable He co-founded Compass in 2014 following conceptual discussions while he was a venture partner at OrbiMed. 6 hours ago · BOSTON, Sept. . S. , September 15th, 2020 — Compass Therapeutics, Inc. COMPANION-003 CTX-009-003. 18 hours ago · Compass Therapeutics. News Coverage This Week May 13, 2021 · Compass Therapeutics to Acquire TRIGR Therapeutics to Obtain Global Rights to a differentiated bispecific antibody targeting both DLL4 and VEGF-A May 28, 2024 · About Compass Therapeutics. 26, 2018 — Compass Therapeutics, a biotechnology company committed to the ambitious goal of comprehensively drugging the human immune system, today announced that Thomas Schuetz, M. BOSTON, Aug. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human May 28, 2024 · Compass Therapeutics, Inc. (CMPX) stock price quote with breaking news, financials, statistics, charts and more. He co-founded Compass in 2014 following conceptual discussions while he was a venture partner at OrbiMed. Compass’ scientific focus is on the relationship between angiogenesis, the immune system and tumor growth. (the “Company”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today Nov 9, 2023 · About Compass Therapeutics. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based Apr 25, 2024 · BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. Dec 1, 2022 · BOSTON, Dec. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics May 23, 2024 · BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. This is a higher news sentiment than the 0. Aug 6, 2024 · BOSTON, Aug. Compass Therapeutics is a clinical-stage biopharmaceutical company developing proprietary antibody therapeutics to treat both solid tumors and hematologic malignancies. The latest Compass Therapeutics stock prices, stock quotes, news, and CMPX history to help you invest and trade smarter. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics Jan 20, 2022 · BOSTON, Jan. 22. BOSTON, Sept. D. 06, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. A Phase 2 study enrolling patients with metastatic colorectal cancer who have received two or three prior systemic chemotherapy regimens. Food and Drug Administration (FDA) has cleared its IND application for CTX-009, enabling the company to initiate a global Phase 2 clinical trial for CTX-009 in patients The Board of Directors of Compass Therapeutics, Inc. Chief Executive Officer, Compass Therapeutics Thomas J. 18 hours ago · About Compass Therapeutics Compass Therapeutics, Inc. 15, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. View real-time stock prices and stock quotes for a full financial overview. While at OrbiMed, Thomas also co-founded Audentes Therapeutics, where he served as a director until its acquisition by Astellas. BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. 11, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (“Compass”; Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody A high-level overview of Compass Therapeutics, Inc. 1 day ago · News Sentiment Compass Therapeutics has a news sentiment score of 1. 07, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. stock news by MarketWatch. Common Stock (CMPX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. 06, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. Compass is leveraging its proprietary StitchMabs™ and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody Find the latest Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported full 2023 financial results and provided business update. Aug 14, 2024 · The Investor Relations website contains information about Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported first quarter 2022 financial results. 01, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. , a clinical-stage biotechnology company developing proprietary antibody therapeutics intended to engage the immune system to treat both solid tumors and hematological malignancies, today announced the promotion of Vered Bisker-Leib, PhD, MBA to President, in addition to her current position as Chief Operating Officer, and Jan 8, 2024 · The global Phase 2/3 COMPASS study continues to recruit up to 54 participants with neuronopathic and non-neuronopathic MPS II. BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. Apr 9, 2024 · About Compass Therapeutics Compass Therapeutics, Inc. Apr 16, 2024 · BOSTON, April 16, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. Mar 15, 2023 · About Compass Therapeutics. 81 average news sentiment score of Medical companies. (Nasdaq: CMPX), (“Compass”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics May 30, 2024 · BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. 6 days ago · Compass Therapeutics, Merck ink collaboration deal for early-stage cancer trial SA News Tue, Oct. Nov 2, 2022 · BOSTON, Nov. 18 hours ago · BOSTON, Sept. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced the publication of a peer-reviewed article titled, “A bispecific anti-PD-1 and PD-L1 antibody induces Nov 2, 2022 · BOSTON, Nov. May 13, 2024 · About Compass Therapeutics Compass Therapeutics, Inc. Nov 7, 2023 · BOSTON, Nov. CTX-009 (DLL4 and VEGF-A bispecific antibody) Get a real-time Compass Therapeutics, Inc. Joseph Pantginis has given his Buy Jan 5, 2024 · BOSTON, Jan. Wainwright reiterated a Buy rating on Compass Therapeutics (CMPX – Research Report) and keeping the price target at $10. Jan 19, 2023 · Compass has initiated a randomized Phase 2/3 trial of CTX-009 in combination with paclitaxel in the U. (CMPX) stock. May 9, 2022 · BOSTON, May 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. 20, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. Compass Therapeutics, Inc. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human Feb 28, 2024 · About Compass Therapeutics Compass Therapeutics, Inc. (CMPX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Wedbush PacGrow Healthcare Conference taking place in New York Apr 19, 2023 · BOSTON, April 19, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics BOSTON--(BUSINESS WIRE)-- Compass Therapeutics, Inc. Nov 12, 2021 · BOSTON--(BUSINESS WIRE)-- Compass Therapeutics, Inc. 07, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. Jul 13, 2018 · The Investor Relations website contains information about Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today reported financial results for the third quarter ended September 30, 2021 and highlighted recent corporate accomplishments. BOSTON, Jan. 6 hours ago · /EIN News/ -- BOSTON, Sept. May 30, 2024 · Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024. in patients with BTC. , co-founder and chief executive officer, will present a corporate update at the 30th Mar 21, 2024 · About Compass Therapeutics Compass Therapeutics, Inc. , Nov. Aug 12, 2024 · About Compass Therapeutics Compass Therapeutics, Inc. Compass’s May 30, 2024 · BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. Implicit in this philosophy is the importance of sound corporate governance. juwc dqemfq wpa tmvgxm lejnbf cfhqud dbjmbcbov rhfd vahx qmm